Covered recipient · General Payments record
STACEY MARIE PARKER-BRUEGGEMANN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$2,096.67
- Reported across 113 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $211.47 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $38.20 | 2 |
| Astellas Pharma US Inc | $33.83 | 1 |
| Genmab U.S., Inc. | $29.02 | 1 |
| Telix Pharmaceuticals | $28.12 | 1 |
| SpringWorks Therapeutics, Inc. | $24.61 | 1 |
| ABBVIE INC. | $23.44 | 1 |
| Acerta Pharma LLC | $18.77 | 1 |
| Merck Sharp & Dohme Corporation | $15.48 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.44 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105184888 | CMS |
| Astellas Pharma US Inc | $33.83 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139452638 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.77 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105731681 | CMS |
| Genmab U.S., Inc. | $29.02 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126832262 | CMS |
| Merck Sharp & Dohme LLC | $15.48 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141792486 | CMS |
| PFIZER INC. | $18.05 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131833518 | CMS |
| PFIZER INC. | $20.15 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131898723 | CMS |
| SpringWorks Therapeutics, Inc. | $24.61 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1085806921 | CMS |
| Telix Pharmaceuticals | $28.12 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1081984712 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.